Jun 2026 $124 M Issued in a merger or acquisition $50 to $250 million 80
Cambrian BioPharma Inc: Private sale, Jun 2026 × Investors in this round 80 investors had bought by the notice of Jul 15, 2026: 80 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $124 M of $130 M offered; $6 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice James Peyer · Executive Officer, Director Juliette Han · Executive Officer, Director Mark Nuttall · Executive Officer Ruth Thieroff-Ekerdt · Executive Officer William DeVaul · Executive Officer Brenton L. Saunders · Director Christian Angermeyer · Director Lorin L. Van Nuland · Director Martin L. Gunhaga · Director Maryanna Saenko · Director Paul L. Farr · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On a merger: “46,210,122 shares were offered in a business combination whereby the Issuer issued 7,988,207 Common and 38,221,915 Preferred shares to shareholders of a certain company in exchange for their shares, increasing the Issuer's ownership to 100%.”Signed by William DeVaul, Chief Legal Officer. Source: SEC Form D, newest notice filed Jul 15, 2026. Read the notice at the SEC .
equity SEC Jun 2023 $23 M No. 4 $10 to $50 million 30
Cambrian BioPharma Inc: Raise no. 4, Jun 2023 × Investors in this round 30 investors had bought by the notice of Jan 13, 2025: 30 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $23 M of $38 M offered; $15 M still to sell
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, other: Simple Agreement for Future Equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice James G. Peyer · Executive Officer, Director Brenton G. Saunders · Director Christian G. Angermayer · Director Maryanna G. Saenko · Director Paul G. Farr · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by James G. Peyer, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 13, 2025. Read the notice at the SEC .
options SEC Oct 2021 $92 M No. 3 $50 to $250 million 56
Cambrian BioPharma Inc: Raise no. 3, Oct 2021 × Investors in this round 56 investors had bought by the notice of Dec 2, 2021: 56 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $92 M of $101 M offered; $9 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice James G. Peyer · Executive Officer, Director, Promoter Christian G. Angermayer · Director Maryanna G. Saenko · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by James G. Peyer, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 2, 2021. Read the notice at the SEC .
equity, options SEC Oct 2020 $28 M No. 2 $10 to $50 million 30
Cambrian BioPharma Inc: Raise no. 2, Oct 2020 × Investors in this round 30 investors had bought by the notice of May 6, 2021: 30 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $28 M of $28 M offered
Smallest investment taken no minimum stated
What was sold equity, debt, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice James G. Peyer · Executive Officer, Director, Promoter Christian G. Angermeyer · Director Maryanna G. Saenko · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The Total Offering amount and Total Amount Sold includes a $4,000,000 convertible promissory note.”Signed by James G. Peyer, Chief Executive Officer. Source: SEC Form D, newest notice filed May 6, 2021. Read the notice at the SEC .
equity, debt, options SEC Oct 2019 $5 M No. 1 $2 to $10 million 5
Cambrian BioPharma Inc: Raise no. 1, Oct 2019 × Investors in this round 5 investors had bought by the notice of Jan 27, 2020: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice James G. Peyer · Executive Officer, Director, Promoter Christian G. Angermeyer · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by James G. Peyer, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 27, 2020. Read the notice at the SEC .
equity, options SEC